NO20055941L - Anvendelse av en sammensetning omfattende en PDE4-inhibitor og en PDE5-inhibitor - Google Patents
Anvendelse av en sammensetning omfattende en PDE4-inhibitor og en PDE5-inhibitorInfo
- Publication number
- NO20055941L NO20055941L NO20055941A NO20055941A NO20055941L NO 20055941 L NO20055941 L NO 20055941L NO 20055941 A NO20055941 A NO 20055941A NO 20055941 A NO20055941 A NO 20055941A NO 20055941 L NO20055941 L NO 20055941L
- Authority
- NO
- Norway
- Prior art keywords
- inhibitor
- pde5
- pde4
- composition
- pde4 inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Oppfinnelsen vedrører den kombinerte administrasjon av en PDE4-inhibitor og en PDE5-inhibitor for behandlingen av en sykdom hvor fosfodiesterase 4 (PDE4) og/eller fosfodiesterase 5 (PDE5) aktivitet er skadelig.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03011609 | 2003-05-22 | ||
PCT/EP2004/050869 WO2004103407A2 (en) | 2003-05-22 | 2004-05-19 | Composition comprising a pde4 inhibitor and a pde5 inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20055941L true NO20055941L (no) | 2005-12-14 |
NO333501B1 NO333501B1 (no) | 2013-06-24 |
Family
ID=33462087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20055941A NO333501B1 (no) | 2003-05-22 | 2005-12-14 | Anvendelse av en sammensetning omfattende en PDE4-inhibitor og en PDE5-inhibitor |
Country Status (23)
Country | Link |
---|---|
US (3) | US20060094723A1 (no) |
EP (1) | EP1628682B1 (no) |
JP (1) | JP2006528229A (no) |
KR (1) | KR20060012004A (no) |
CN (1) | CN1791429A (no) |
AU (1) | AU2004241749B2 (no) |
BR (1) | BRPI0410326A (no) |
CA (1) | CA2525946C (no) |
CO (1) | CO5660275A2 (no) |
EA (1) | EA012279B1 (no) |
EC (1) | ECSP056173A (no) |
GE (1) | GEP20084342B (no) |
IL (1) | IL171306A (no) |
IS (1) | IS8181A (no) |
MA (1) | MA27855A1 (no) |
MX (1) | MXPA05012302A (no) |
NO (1) | NO333501B1 (no) |
NZ (1) | NZ544040A (no) |
RS (1) | RS52730B (no) |
TN (1) | TNSN05265A1 (no) |
UA (1) | UA83041C2 (no) |
WO (1) | WO2004103407A2 (no) |
ZA (1) | ZA200508116B (no) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
ME00524B (me) | 2003-03-10 | 2011-10-10 | Astrazeneca Ab | Novi postupak za dobijanje roflumilasta |
US7776893B2 (en) | 2003-09-05 | 2010-08-17 | Nycomed Gmbh | Use of PDE4 inhibitors for the treatment of diabetes mellitus |
EP1755595A1 (en) * | 2004-05-10 | 2007-02-28 | Altana Pharma AG | Use of roflumilast for the prophylaxis or treatment of emphysema |
WO2006094942A1 (en) * | 2005-03-08 | 2006-09-14 | Nycomed Gmbh | Roflumilast for the treatment of diabetes mellitus |
EA015382B1 (ru) * | 2005-03-08 | 2011-08-30 | Никомед Гмбх | Применение рофлумиласта для лечения сахарного диабета типа 2 |
JP5383183B2 (ja) | 2005-03-16 | 2014-01-08 | タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロフルミラストを含有する矯味された剤形 |
DE102005016345A1 (de) * | 2005-04-09 | 2006-10-12 | Bayer Healthcare Ag | Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten |
MX2007012711A (es) * | 2005-04-19 | 2008-01-11 | Nycomed Gmbh | Roflumilast para el tratamiento de hipertension pulmonar. |
NL2000291C2 (nl) | 2005-11-10 | 2009-02-17 | Pfizer Prod Inc | 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan. |
ATE535244T1 (de) | 2006-07-05 | 2011-12-15 | Nycomed Gmbh | Kombination aus atorvastatin mit einem phosphodiesterase-4-hemmer zur behandlung von entzündlichen lungenerkrankungen |
WO2008041118A2 (en) * | 2006-10-04 | 2008-04-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
WO2010013925A2 (en) * | 2008-07-31 | 2010-02-04 | Dong-A Pharmaceutical. Co., Ltd. | Pharmacological composition for prevention and treatment of respiratory disease containing pyrazolopyrimidinone compound or pharmaceutically acceptable salts thereof |
CN103826638B (zh) * | 2011-09-09 | 2015-11-25 | Sk化学公司 | 含有pde5 抑制剂的减少皮肤皱纹的组合物 |
SG11201407919WA (en) * | 2012-05-31 | 2014-12-30 | Phenex Pharmaceuticals Ag | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma] |
US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
EP3165224A1 (en) | 2015-11-09 | 2017-05-10 | Albert-Ludwigs-Universität Freiburg | Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders |
US10058545B2 (en) * | 2016-08-09 | 2018-08-28 | Cipla Limited | Method of treating pulmonary arterial hypertension |
CN107648224A (zh) * | 2017-10-31 | 2018-02-02 | 泰州中国医药城中医药研究院 | 一种治疗和预防心力衰竭药物及其在制药中的应用 |
US20210031012A1 (en) | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
CN108976107B (zh) * | 2018-08-23 | 2021-03-23 | 南方医科大学 | 3-芳基-4-烷氧基苄胺衍生物及其制备方法和应用 |
KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
US20230124467A1 (en) * | 2020-03-03 | 2023-04-20 | Mios Pharmaceuticals Limited | Compounds and methods for treating diseases and/or conditions caused by coronavirus |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
EP0706513B1 (de) | 1993-07-02 | 2002-05-15 | Byk Gulden Lomberg Chemische Fabrik GmbH | Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
KR970705562A (ko) * | 1994-08-29 | 1997-10-09 | 오노다 마사요시 | 신규한 나프티리딘 유도체 및 이의 의약 조성물(Novel naphthyridine derivatives and medicinal composition thereof) |
US6127363A (en) * | 1997-10-28 | 2000-10-03 | Vivus, Inc. | Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction |
HU230154B1 (hu) | 1997-11-12 | 2015-09-28 | Bayer Intellectual Property Gmbh | Eljárás 2-es helyzetben fenil-szubszituenst hordozó imidazo-triazinon-származékok előállítására |
US6417190B1 (en) * | 1998-12-17 | 2002-07-09 | Boehringer Ingelheim Pharma Kg | Tricyclic nitrogen heterocycles as PDE IV inhibitors |
TWI224966B (en) * | 1999-11-02 | 2004-12-11 | Pfizer | Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient |
CZ20032491A3 (cs) * | 2001-02-15 | 2004-01-14 | Altana Pharma Ag | Ftalazinonpiperidinové deriváty |
JP2004530705A (ja) * | 2001-05-25 | 2004-10-07 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 閉塞性気道疾患及びその他の炎症性疾患を治療するためのpde4インヒビター及びチオトロピウム又はその誘導体の組み合わせ |
US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
GB0202254D0 (en) * | 2002-01-31 | 2002-03-20 | Pfizer Ltd | Prevention of scarring |
US20030216407A1 (en) * | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
-
2004
- 2004-05-19 JP JP2006530210A patent/JP2006528229A/ja active Pending
- 2004-05-19 CN CNA2004800133493A patent/CN1791429A/zh active Pending
- 2004-05-19 GE GEAP20049115A patent/GEP20084342B/en unknown
- 2004-05-19 US US10/556,888 patent/US20060094723A1/en not_active Abandoned
- 2004-05-19 KR KR1020057021796A patent/KR20060012004A/ko active Search and Examination
- 2004-05-19 RS YU20050858A patent/RS52730B/sr unknown
- 2004-05-19 BR BRPI0410326-2A patent/BRPI0410326A/pt active Search and Examination
- 2004-05-19 CA CA2525946A patent/CA2525946C/en not_active Expired - Fee Related
- 2004-05-19 EA EA200501690A patent/EA012279B1/ru not_active IP Right Cessation
- 2004-05-19 NZ NZ544040A patent/NZ544040A/en not_active IP Right Cessation
- 2004-05-19 EP EP04766017.0A patent/EP1628682B1/en not_active Expired - Lifetime
- 2004-05-19 WO PCT/EP2004/050869 patent/WO2004103407A2/en active Application Filing
- 2004-05-19 MX MXPA05012302A patent/MXPA05012302A/es active IP Right Grant
- 2004-05-19 UA UAA200511710A patent/UA83041C2/ru unknown
- 2004-05-19 AU AU2004241749A patent/AU2004241749B2/en not_active Ceased
-
2005
- 2005-10-07 ZA ZA200508116A patent/ZA200508116B/en unknown
- 2005-10-09 IL IL171306A patent/IL171306A/en not_active IP Right Cessation
- 2005-10-18 TN TNP2005000265A patent/TNSN05265A1/en unknown
- 2005-11-17 EC EC2005006173A patent/ECSP056173A/es unknown
- 2005-12-12 MA MA28653A patent/MA27855A1/fr unknown
- 2005-12-14 NO NO20055941A patent/NO333501B1/no not_active IP Right Cessation
- 2005-12-14 IS IS8181A patent/IS8181A/is unknown
- 2005-12-16 CO CO05126935A patent/CO5660275A2/es active IP Right Grant
-
2010
- 2010-05-24 US US12/785,973 patent/US20100234382A1/en not_active Abandoned
-
2012
- 2012-04-12 US US13/445,675 patent/US20120196867A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ECSP056173A (es) | 2006-04-19 |
EA012279B1 (ru) | 2009-08-28 |
US20100234382A1 (en) | 2010-09-16 |
EP1628682B1 (en) | 2013-09-25 |
IS8181A (is) | 2005-12-14 |
CA2525946A1 (en) | 2004-12-02 |
RS52730B (sr) | 2013-08-30 |
BRPI0410326A (pt) | 2006-05-23 |
AU2004241749B2 (en) | 2010-03-25 |
NO333501B1 (no) | 2013-06-24 |
JP2006528229A (ja) | 2006-12-14 |
NZ544040A (en) | 2009-03-31 |
UA83041C2 (ru) | 2008-06-10 |
MA27855A1 (fr) | 2006-04-03 |
EP1628682A2 (en) | 2006-03-01 |
US20060094723A1 (en) | 2006-05-04 |
KR20060012004A (ko) | 2006-02-06 |
RS20050858A (en) | 2007-12-31 |
AU2004241749A1 (en) | 2004-12-02 |
GEP20084342B (en) | 2008-03-25 |
MXPA05012302A (es) | 2006-01-30 |
WO2004103407A3 (en) | 2005-02-17 |
CA2525946C (en) | 2013-01-29 |
EA200501690A1 (ru) | 2006-06-30 |
US20120196867A1 (en) | 2012-08-02 |
TNSN05265A1 (en) | 2007-07-10 |
WO2004103407A2 (en) | 2004-12-02 |
ZA200508116B (en) | 2007-01-31 |
CN1791429A (zh) | 2006-06-21 |
CO5660275A2 (es) | 2006-07-31 |
IL171306A (en) | 2013-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20055941L (no) | Anvendelse av en sammensetning omfattende en PDE4-inhibitor og en PDE5-inhibitor | |
ES2195785A1 (es) | Nuevos derivados de piridazin-3(2h)-ona. | |
MXPA04003668A (es) | Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos. | |
WO2005032471A3 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
EP1562897A4 (en) | PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER | |
NO2007010I2 (no) | Sitagliptin, eventuelt i form av et farmasøytisk akseptabelt salt | |
NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
NO20024005D0 (no) | Pteridinforbindelser for behandling av psoriasis | |
CY1111700T1 (el) | Αναστολεις των νουκλεοζιτικων φωσφορυλασων και νουκλεοζιδασων | |
WO2004062625A3 (en) | Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease | |
WO2005004803A3 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease | |
DE60330485D1 (de) | Zur behandlung von diabetes | |
HUP0303082A2 (hu) | Szubsztituált indolil-oxo-acetil-piperazinszármazékok, ezeket tartalmazó készítmények és vírusellenes alkalmazásuk | |
DE69911448D1 (de) | Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen | |
ATE283856T1 (de) | Zyklische guanosine 3',5'-monophosphate phosphodiesterase inhibitoren | |
WO2005051914A8 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
HUP0301991A2 (hu) | IL-18-inhibitorok alkalmazása atheroszklerózis kezelésére és/vagy megelżzésére | |
IS6967A (is) | Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma | |
ATE547104T1 (de) | Zusammensetzung enthaltend einen lungensurfactant und sildenafil zur behandlung von lungenerkrankungen | |
SE0302304D0 (sv) | Novel compounds | |
EE200300328A (et) | IL-18 inhibiitorite kasutamine südamehaiguse raviks ja/või ennetamiseks | |
FR2842422B1 (fr) | Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations | |
ATE325115T1 (de) | Pyrimidinderivate als selektive cox-2-inhibitoren | |
HUP0500078A2 (hu) | PDE inhibitort és leukotrién antagonistát tartalmazó kombinált gyógyszerkészítmény | |
NO20033541L (no) | Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CREP | Change of representative |
Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104 |
|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: TAKEDA GMBH, DE |
|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: TAKEDA GMBH, DE |
|
MM1K | Lapsed by not paying the annual fees |